These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21762928)

  • 1. Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).
    Nobili F; Morbelli S; Arnaldi D; Ferrara M; Campus C; Brugnolo A; Mazzei D; Mehrdad N; Sambuceti G; Rodriguez G
    J Neurol Sci; 2011 Nov; 310(1-2):31-5. PubMed ID: 21762928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.
    Arnaldi D; Morbelli S; Morrone E; Campus C; Nobili F
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):55-67. PubMed ID: 22460160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.
    Garcia-Garcia D; Clavero P; Gasca Salas C; Lamet I; Arbizu J; Gonzalez-Redondo R; Obeso JA; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1767-77. PubMed ID: 22872307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease.
    Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Suzuki K; Hasegawa T; Aoki M; Takeda A; Mori E
    J Neurol Sci; 2017 Jan; 372():288-293. PubMed ID: 28017230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment.
    Lyoo CH; Jeong Y; Ryu YH; Rinne JO; Lee MS
    Eur Neurol; 2010; 64(2):65-73. PubMed ID: 20606450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.
    Jokinen P; Scheinin N; Aalto S; Någren K; Savisto N; Parkkola R; Rokka J; Haaparanta M; Röyttä M; Rinne JO
    Parkinsonism Relat Disord; 2010 Dec; 16(10):666-70. PubMed ID: 20870446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.
    Tang Y; Ge J; Liu F; Wu P; Guo S; Liu Z; Wang Y; Wang Y; Ding Z; Wu J; Zuo C; Wang J
    PLoS One; 2016; 11(4):e0152716. PubMed ID: 27064684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease.
    Nobili F; Arnaldi D; Campus C; Ferrara M; De Carli F; Brugnolo A; Dessi B; Girtler N; Morbelli S; Abruzzese G; Sambuceti G; Rodriguez G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2209-18. PubMed ID: 21744112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in
    Wu L; Liu FT; Ge JJ; Zhao J; Tang YL; Yu WB; Yu H; Anderson T; Zuo CT; Chen L; Wang J
    Hum Brain Mapp; 2018 Dec; 39(12):4652-4662. PubMed ID: 29999569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.
    Gasca-Salas C; Clavero P; García-García D; Obeso JA; Rodríguez-Oroz MC
    Hum Brain Mapp; 2016 Mar; 37(3):968-77. PubMed ID: 26663702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].
    Homenko JG; Susin DS; Kataeva GV; Irishina JA; Zavolokov IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):46-51. PubMed ID: 28638030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.
    Klein JC; Eggers C; Kalbe E; Weisenbach S; Hohmann C; Vollmar S; Baudrexel S; Diederich NJ; Heiss WD; Hilker R
    Neurology; 2010 Mar; 74(11):885-92. PubMed ID: 20181924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
    Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
    Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
    Hirano S; Shinotoh H; Eidelberg D
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive profile and 18F-fluorodeoxyglucose PET study in LRRK2-related Parkinson's disease.
    De Rosa A; Peluso S; De Lucia N; Russo P; Annarumma I; Esposito M; Manganelli F; Brunetti A; De Michele G; Pappatà S
    Parkinsonism Relat Disord; 2018 Feb; 47():80-83. PubMed ID: 29249679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease.
    Xu Y; Yang J; Hu X; Shang H
    J Neurol; 2016 Jun; 263(6):1178-87. PubMed ID: 27113603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism.
    Pappatà S; Santangelo G; Aarsland D; Vicidomini C; Longo K; Bronnick K; Amboni M; Erro R; Vitale C; Caprio MG; Pellecchia MT; Brunetti A; De Michele G; Salvatore M; Barone P
    Neurology; 2011 Oct; 77(14):1357-62. PubMed ID: 21940621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI.
    Massa F; Arnaldi D; De Cesari F; Girtler N; Brugnolo A; Grazzini M; Bauckneht M; Meli R; Morbelli S; Pardini M; Sambuceti G; De Carli F; Tiraboschi P; Nobili F
    Neurobiol Aging; 2019 Apr; 76():9-17. PubMed ID: 30611093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
    Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.
    Mito Y; Yoshida K; Yabe I; Makino K; Hirotani M; Tashiro K; Kikuchi S; Sasaki H
    Clin Neurol Neurosurg; 2005 Aug; 107(5):396-403. PubMed ID: 16023534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.